$TSEM

Tue: Chip cos fall sharply on flat TASE

The Tel Aviv Stock Exchange was mostly flat, with the Tel Aviv 35 Index up 0.04%. Chip companies led declines, with Tower Semiconductor (TSEM) down 8.71%, Camtek (CAMT) down 5.63%, and Nova (NVMI) down 5.46%. Banks and Shufersal (SAE) rose, with Bank Hapoalim (POLI) up 1.85% and Shufersal up 4.58%.

Original reporting
Published Aug 18, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 7:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tue: Chip cos fall sharply on flat TASE — source image
Decision brief

The 30-second read

$TSEMBearishLow
01

Why it matters

The only actionable signal is the magnitude of same-day declines in TASE-listed chip/tech names (TSEM, CAMT, NVMI) alongside a 1.6% Tech Index drop.

02

Market read

Traders can use the reported dispersion to manage short-term exposure to TASE chip/tech names, but there is no new fundamental catalyst disclosed.

03

What to watch

The article lacks catalysts for the chip names; without news, traders may be over-attributing the move to fundamentals.

Relevance 4/10Novelty 2/10Timing: intraday session wrap, evening of 2026-08-18

Background

This is a daily TASE market wrap noting index performance, FX levels, and which sectors and stocks led gains and losses.

Company-level read

Ticker impact

$TSEMBearishMedium confidence
Context

Tower Semiconductor fell 8.71% as the Tech Index dropped, making it the largest decliner on the Tel Aviv 35 Index today.

Expected impact

Bearish bias for near-term trading momentum; watch for follow-through or mean reversion after the outsized move.

Evidence & confidence

The article provides a large intraday percentage decline and identifies it as the biggest fall, but gives no catalyst beyond sector weakness.

$CAMTBearishMedium confidence
Context

Camtek dropped 5.63% alongside the chip-led weakness in the Tech Index.

Expected impact

Lower near-term risk appetite for CAMT until sector tone stabilizes.

Evidence & confidence

The text reports the magnitude of the decline but does not cite company-specific news.

$NVMIBearishMedium confidence
Context

Nova Ltd. fell 5.46% as chip companies led the Tech Index lower.

Expected impact

Tactical bearish bias while the chip complex remains under pressure.

Evidence & confidence

The article reports the percentage drop and sector context, but no distinct NVMI catalyst.

$ENLTNeutralLow confidence
Context

Enlight Renewable Energy rose 0.97% during a session where the Tech Index fell 1.6% led by chip companies.

Expected impact

Mildly supportive for ENLT relative performance, but not a standalone catalyst.

Evidence & confidence

The article only provides the day’s move and does not explain why ENLT traded higher.

$TEVABullishLow confidence
Context

Teva Pharmaceutical Industries rose 2.50% while chip companies dragged the Tech Index lower.

Expected impact

Near-term relative strength possible, but direction depends on whether the chip selloff broadens.

Evidence & confidence

No company-specific news is provided, only the intraday price change and index context.

Market effects

Chip companies were the main drag on the Tech Index, implying correlated downside risk across TASE-listed semis/tech exposures.

Israel equities were broadly flat overall, but tech/chips showed clear internal dispersion.

Limited direct global linkage in the text; mainly a local TASE sector tape read-through.

Counterpoint

The broader indices were nearly flat, so the chip selloff may be a short-lived rotation rather than a fundamental repricing.

Key entities

  • Tel Aviv 35 Index

    Up 0.04% to 4,176.34 points, indicating the overall market was flat.

  • Tech Index

    Down 1.6%, led by chip companies, signaling sector-specific weakness.

  • Tower Semiconductor

    Down 8.71% as the biggest fall on the Tel Aviv 35 Index.

Related articles

$TEVAMedAI 8/10

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette syndrome

Teva Pharmaceutical (TEVA) presented data on ecopipam, an investigational treatment for pediatric Tourette syndrome. Studies showed clinically meaningful tic severity reduction within two months and sustained over a year. The drug maintained efficacy regardless of co-occurring psychiatric conditions. Ecopipam has FDA Priority Review and Orphan Drug designation.

$TEVAMed

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses

Teva Pharmaceuticals presented new data on ecopipam, an investigational drug for pediatric Tourette syndrome, showing clinically meaningful tic reductions within 8 weeks and sustained benefits through 18 months. The findings, presented at the International Congress of Parkinson’s Disease and Movement Disorders, include pooled post hoc analyses and interim results from ongoing studies. Ecopipam is under FDA priority review, with a target action date in Q1 2027.

$TEVAHigh

Teva secures FDA approval for Degevma biosimilar

Teva received FDA approval for DEGEVMA, a biosimilar to Xgeva, across all indications. This follows the March 2026 approval of PONLIMSI, completing Teva's U.S. denosumab biosimilar portfolio. The company aims to expand access to oncology-related bone disease and osteoporosis treatments, reducing healthcare costs.

$TEVAMed

Teva’s Tourette drug shows rapid & sustained tic reduction in new data

Teva Pharmaceuticals presented new data for ecopipam, an investigational treatment for pediatric Tourette syndrome, showing rapid and sustained tic reduction. In trials, 69.8% of patients saw a 25% reduction in tic severity within eight weeks, with benefits lasting over a year. The drug is under FDA Priority Review, and Teva aims for approval as the first new therapy in over a decade.

$ABBVMed

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration selected 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot program starting January 1. The program tests a rebate model for 21 discounted drugs under the 340B program. The HRSA oversees the initiative, aiming to address compliance proactively. The program is contentious, with pharmaceutical companies and hospitals disputing its impact.

$TEVAMed

Teva Presents Post Hoc Ecopipam Data Ahead of 2027 FDA Decision

Teva presented post hoc data on ecopipam for pediatric Tourette syndrome at a conference, ahead of a 2027 FDA decision. The data aims to clarify which patients benefit most, with the FDA's review window open. Ecopipam, a selective dopamine D1 receptor antagonist, showed favorable safety and efficacy in trials, differing from traditional D2-targeting antipsychotics.